menu
    • menu
    [{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The Medicines Patent Pool \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"The Medicines Patent Pool \/ Merck & Co"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Strides Pharma Science","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The Medicines Patent Pool \/ Strides Pharma Science","highestDevelopmentStatusID":"15","companyTruncated":"The Medicines Patent Pool \/ Strides Pharma Science"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The Medicines Patent Pool \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"The Medicines Patent Pool \/ Undisclosed"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The Medicines Patent Pool \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"The Medicines Patent Pool \/ Pfizer Inc"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"The Medicines Patent Pool \/ Aurobindo Pharma Limited","highestDevelopmentStatusID":"4","companyTruncated":"The Medicines Patent Pool \/ Aurobindo Pharma Limited"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Nilotinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The Medicines Patent Pool \/ Aurobindo Pharma Limited","highestDevelopmentStatusID":"15","companyTruncated":"The Medicines Patent Pool \/ Aurobindo Pharma Limited"}]

    Find Clinical Drug Pipeline Developments & Deals by The Medicines Patent Pool

    Menu

    The Medicines Patent Pool

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            The Medicines Patent Pool

                            Switzerland arrow
                            Cophex
                            Not Confirmed

                            The Medicines Patent Pool

                            Switzerland arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nilotinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Aurobindo Pharma Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Aurobindo Pharma Arm Signs Pact with Medicines Patent Pool to Develop Anti-Cancer Drug

                            Details : The agreement aims to to develop and market an anti-cancer drug, Tasigna (nilotinib), a transduction inhibitor, used for treatment of chronic myeloid leukemia.

                            Product Name : Tasigna-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 23, 2023

                            Lead Product(s) : Nilotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Aurobindo Pharma Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            The Medicines Patent Pool

                            Switzerland arrow
                            Cophex
                            Not Confirmed

                            The Medicines Patent Pool

                            Switzerland arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cabotegravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Aurobindo Pharma Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Med Patent Pool Signs with Aurobindo, Cipla & Viatris for Generic HIV Prevention Medicine

                            Details : ViiV Healthcare sublicence agreements with Aurobindo, Cipla and Viatris to manufacture generic versions of cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis.

                            Product Name : Apretude-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 30, 2023

                            Lead Product(s) : Cabotegravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Aurobindo Pharma Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            The Medicines Patent Pool

                            Switzerland arrow
                            Cophex
                            Not Confirmed

                            The Medicines Patent Pool

                            Switzerland arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nirmatrelvir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Strides Pharma Science

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Strides Partners with Medicines Patent Pool (MPP) to Commercialize the Generic Version of Pfizer’s COVID-19 ...

                            Details : The agreement aims to commercialize a generic version of Pfizer’s COVID-19 oral treatment, Paxlovid (nirmatrelvir and ritonavir), indicated for the treatment of mild-to-moderate coronavirus disease, in 95 low and middle-income markets.

                            Product Name : Nirmatrelvir-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 21, 2022

                            Lead Product(s) : Nirmatrelvir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Strides Pharma Science

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            The Medicines Patent Pool

                            Switzerland arrow
                            Cophex
                            Not Confirmed

                            The Medicines Patent Pool

                            Switzerland arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nirmatrelvir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            35 Generic Manufacturers Sign Agreements With MPP to Produce Low-Cost, Generic Versions of Pfizer's Oral COVID...

                            Details : Sublicences will allow manufacturers (Teva, Cipla, Biocon, Amneal, Viatris, Torrent, MSN, Sun Pharma, Cadila, Glenmark, Fosun, Beximco, Celltrion & others) to produce the raw materials for generic of Pfizer’s COVID-19 nirmatrelvir and finished drug co-...

                            Product Name : Nirmatrelvir-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 17, 2022

                            Lead Product(s) : Nirmatrelvir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            The Medicines Patent Pool

                            Switzerland arrow
                            Cophex
                            Not Confirmed

                            The Medicines Patent Pool

                            Switzerland arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nirmatrelvir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Cand...

                            Details : Under the terms of license agreement between Pfizer and MPP, qualified generic medicine manufacturers worldwide that are granted sub-licenses will be able to supply PF-07321332 in combination with ritonavir to 95 countries, covering up to approx 53% of t...

                            Product Name : Nirmatrelvir-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 16, 2021

                            Lead Product(s) : Nirmatrelvir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            The Medicines Patent Pool

                            Switzerland arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            The Medicines Patent Pool

                            Switzerland arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Molnupiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Or...

                            Details : Under the terms of the agreement, MPP, through the license granted by Merck, will be permitted to further license non-exclusive sublicenses to manufacturers and diversify the manufacturing base or WHO-prequalified molnupiravir to countries covered by the...

                            Product Name : EIDD-2801

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 27, 2021

                            Lead Product(s) : Molnupiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth